Cost-effectiveness analysis, prevention of atopic dermatitis by oral application of bacterial lysate in newborns/small children

Prophylactic treatment with bacterial lysate of infants with single heredity for atopy for 26 weeks in the 1st year of life is cost-effective at the age of 3 and 6 years, i.e. prophylactic use of bacterial lysate generated lower costs by leading to lower prevalence compared to placebo. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2013

MoreLess

Year of publication:	2013
Authors:	Kiencke, Peter ; Viehmann, Kristina ; Rychlik, Reinhard
Published in:	The European Journal of Health Economics. - Springer. - Vol. 14.2013, 6, p. 995-1002
Publisher:	Springer
Subject:	Cost-effectiveness \| Atopic dermatitis \| Newborns \| Small children \| Prophylactic treatment \| Escherichia coli \| Enterococus faecalis \| Sterile bacterial lysate \| Model \| Decision tree

Online Resource

Check full text access |

More access options

Check Google Scholar

In German libraries (KVK)

I need help

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10010993918